 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- LiPlaCis (liposomal cisplatin) / Smerud Medical Research
Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer. (On Demand | Hall A; Poster Bd # 328) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1831;
P1/2
Further, this is the first clinical study to prospectively validate DRP as a method to identify responders to chemotherapy cisplatin. 1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609.
- || LiPlaCis (liposomal cisplatin) / Smerud Medical Research, Chosa Oncology
Trial completion, Metastases: Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - Feb 24, 2022
P1/2, N=50, Completed, Sponsor: Allarity Therapeutics
1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609. Active, not recruiting --> Completed
- | LiPlaCis (liposomal cisplatin) / Smerud Medical Research, Chosa Oncology
Trial completion date, Trial primary completion date, Metastases: Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - Aug 18, 2021
P1/2, N=50, Active, not recruiting, Sponsor: Allarity Therapeutics
Active, not recruiting --> Completed Trial completion date: Apr 2021 --> Oct 2021 | Trial primary completion date: Apr 2021 --> Oct 2021
- | LiPlaCis (liposomal cisplatin) / Smerud Medical Research, Chosa Oncology
Trial completion date, Trial primary completion date, Metastases: Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - Mar 1, 2021
P1/2, N=50, Active, not recruiting, Sponsor: Oncology Venture
Trial completion date: Apr 2021 --> Oct 2021 | Trial primary completion date: Apr 2021 --> Oct 2021 Trial completion date: Dec 2020 --> Apr 2021 | Trial primary completion date: Dec 2020 --> Apr 2021
- | LiPlaCis (liposomal cisplatin) / Smerud Medical Research, Chosa Oncology
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - Oct 27, 2020
P1/2, N=50, Active, not recruiting, Sponsor: Oncology Venture
Trial completion date: Dec 2020 --> Apr 2021 | Trial primary completion date: Dec 2020 --> Apr 2021 Recruiting --> Active, not recruiting | Trial completion date: Sep 2020 --> Dec 2020 | Trial primary completion date: Sep 2020 --> Dec 2020
- | LiPlaCis (liposomal cisplatin) / Allarity Therap, Lipoplatin (cisplatin liposomal) / Regulon
Journal: The latest advances of Cisplatin liposomal formulations: essentials for preparation and analysis. (Pubmed Central) - Mar 3, 2020
Cisplatin resistance is another challenge which should be prevented by higher loading capacity. Charge dependent interactions should also be highly considered especially in the preparation step.
- | LiPlaCis (liposomal cisplatin) / Smerud Medical Research, Chosa Oncology
Trial completion date, Trial primary completion date, Metastases: Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=50, Recruiting, Sponsor: Oncology Venture
Charge dependent interactions should also be highly considered especially in the preparation step. Trial completion date: May 2019 --> Sep 2020 | Trial primary completion date: May 2019 --> Sep 2020
- ||| LiPlaCis (liposomal cisplatin) / Oncology Venture
Clinical, FDA event: #FDA grants IDE approval to use #OncologyVenture’s #LiPlaCis DRP for patient selection in a pivotal Phase 3 study $OV https://t.co/lNqnwBu4yL (Twitter) - Aug 18, 2019
- LiPlaCis (liposomal cisplatin) / Smerud Medical Research, Chosa Oncology
Trial primary completion date, Metastases: Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - Jan 30, 2018
P1/2, N=40, Recruiting, Sponsor: Oncology Venture
Trial completion date: May 2019 --> Sep 2020 | Trial primary completion date: May 2019 --> Sep 2020 Trial primary completion date: May 2018 --> May 2019
- LiPlaCis (liposomal cisplatin) / Smerud Medical Research, Chosa Oncology
Trial primary completion date, Metastases: Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - Aug 3, 2017
P1/2, N=35, Recruiting, Sponsor: Oncology Venture
Trial primary completion date: May 2018 --> May 2019 Trial primary completion date: May 2019 --> May 2018
- LiPlaCis (liposomal cisplatin) / Smerud Medical Research, Chosa Oncology
Trial primary completion date, Metastases: Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - Aug 2, 2017
P1/2, N=35, Recruiting, Sponsor: Oncology Venture
Trial primary completion date: May 2019 --> May 2018 Trial primary completion date: May 2018 --> May 2019
- LiPlaCis (liposomal cisplatin) / Smerud Medical Research, Chosa Oncology
Phase classification, Trial primary completion date, Metastases: Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - Mar 3, 2017
P1/2, N=35, Recruiting, Sponsor: Oncology Venture
Trial primary completion date: May 2018 --> May 2019 Phase classification: P1 --> P1/2 | Trial primary completion date: May 2017 --> May 2018
- LiPlaCis (liposomal cisplatin) / Smerud Medical Research, Chosa Oncology
Trial primary completion date, Metastases: Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - Mar 4, 2016
P1, N=35, Recruiting, Sponsor: LiPlasome Pharma
Phase classification: P1 --> P1/2 | Trial primary completion date: May 2017 --> May 2018 Trial primary completion date: May 2016 --> May 2017
- LiPlaCis (liposomal cisplatin) / Smerud Medical Research, Chosa Oncology
Enrollment change, Trial primary completion date, Metastases: Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - Apr 14, 2015
P1, N=35, Recruiting, Sponsor: LiPlasome Pharma
Trial primary completion date: May 2016 --> May 2017 N=28 --> 35 | Trial primary completion date: May 2015 --> May 2016
- LiPlaCis (liposomal cisplatin) / Smerud Medical Research, Chosa Oncology
Trial primary completion date, Metastases: Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - Jun 27, 2014
P1, N=28, Recruiting, Sponsor: LiPlasome Pharma
N=28 --> 35 | Trial primary completion date: May 2015 --> May 2016 Trial primary completion date: Apr 2014 --> May 2015
- LiPlaCis (liposomal cisplatin) / Smerud Medical Research, Chosa Oncology
Enrollment change, Trial primary completion date, Metastases: Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - Jun 27, 2014
P1, N=28, Recruiting, Sponsor: LiPlasome Pharma
Trial primary completion date: Apr 2014 --> May 2015 N=18 --> 28 | Trial primary completion date: Apr 2014 --> May 2015
- | LiPlaCis (liposomal cisplatin) / Smerud Medical Research, Chosa Oncology
New P1 trial, Metastases: Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (clinicaltrials.gov) - May 21, 2013
P1, N=18, Recruiting, Sponsor: LiPlasome Pharma